Authors:
AVENT KM
RIKER RR
FRASER GL
VANDERSCHYF CJ
USUKI E
POND SM
Citation: Km. Avent et al., METABOLISM OF HALOPERIDOL TO PYRIDINIUM SPECIES IN PATIENTS RECEIVINGHIGH-DOSES INTRAVENOUSLY - IS HPTP AN INTERMEDIATE, Life sciences, 61(24), 1997, pp. 2383-2390
Citation: Rr. Riker et al., MOVEMENT-DISORDERS ASSOCIATED WITH WITHDRAWAL FROM HIGH-DOSE INTRAVENOUS HALOPERIDOL THERAPY IN DELIRIOUS ICU PATIENTS, Chest, 111(6), 1997, pp. 1778-1781
Citation: Rr. Riker et Bw. White, THE EFFECT OF PHYSICIAN EDUCATION ON THE RATES OF DONATION REQUEST AND TISSUE DONATION, Transplantation, 59(6), 1995, pp. 880-884
Citation: Rr. Riker et al., CONTINUOUS-INFUSION OF HALOPERIDOL CONTROLS AGITATION IN CRITICALLY ILL PATIENTS, Critical care medicine, 22(3), 1994, pp. 433-440
Citation: Gl. Fraser et Rr. Riker, VISUAL COMPATIBILITY OF HALOPERIDOL LACTATE WITH INJECTABLE SOLUTIONS, American journal of hospital pharmacy, 51(7), 1994, pp. 905-906